- News & Analysis
- Home
- Latest News
- Reports
- Podcast
- The CVC Funding Round Database
- The CVC Directory
- University
- Video
- Subscribe
- Newsletters
- Events
Page 153
Xpeng extracts $1.5bn from initial public offering
The Alibaba, Xiaomi, Foxconn, UCar and Duowan-backed smart electric carmaker has floated in the US through an offering valuing it in excess of $21bn.
Aug 27, 2020Desktop Metal irons out $2.5bn reverse merger
Desktop Metal, backed by a large consortium of corporates, will merge with special purpose acquisition company Trine to list on the NYSE at a $2.5bn valuation.
Aug 27, 2020Google to add $100m to Amwell IPO
The Teva, Allianz and Takeda-backed telehealth technology producer has filed to raise up to $100m in an offering that will be boosted by another $100m from Google.
Aug 27, 2020Cisco signs up for BabbleLabs acquisition
Dell Technologies Capital and Intel Capital are set to exit the audio enhancement technology provider, which has agreed to be bought by Cisco.
Aug 26, 2020Govertis makes its way to ElevenPaths
The Telefónica subsidiary has bought cyber risk consultancy and software producer Govertis having previously invested through subsidiary ElevenPaths.
Aug 26, 2020Ant Group advances to IPO filings
Alibaba's financial services spinoff has officially filed for a dual listing in Shanghai and Hong Kong that could potentially raise $30bn.
Aug 26, 2020Palantir reveals filing for direct listing
The Sompo, Fujitsu and Relx-backed data miner, which has raised some $2.7bn in venture funding, has chosen the New York Stock Exchange to list its shares.
Aug 26, 2020Bionano Genomics takes up Lineagen
University of Utah autism diagnosis service provider Lineagen has been snapped up in a transaction worth at least $9.6m in cash, stocks and liabilities.
Aug 26, 2020Yumanity and Proteostasis pursue reverse merger
Yumanity Therapeutics will take over Nasdaq-listed Proteostasis in a reverse merger after raising more than $100m from investors including Biogen, Merck & Co, Pfizer and Sanofi.
Aug 26, 2020Acadia absorbs Cersci for $52.5m
UT Dallas spinout Cersci Therapeutics has been acquired in a deal potentially worth nearly $940m, including a $52.5m upfront payment.
Aug 26, 2020About us
GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits the GCV Leadership Society, providing privileged access to all our services and resources.
Navigation
test regLogin
Not yet subscribed?
We use cookies to enhance your browsing experience and analyse our traffic. By clicking "Accept All", you consent to our use of cookies. Accept Read MorePrivacy & Cookies PolicyPrivacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.


